CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors --Study highlights wide range of pediatric cancers in which NTRK fusions are more likely to occur, which could help prioritize testing for targeted treatment with FDA-approved TRK inhibitors-- News provided by Share this article Share this article PHILADELPHIA, Jan. 15, 2021 /PRNewswire/ -- In a large study of pediatric cancer patients, researchers from Children's Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fus...